The strategy hinges on an engineered bifunctional fusion molecule called anti-TCRβ-IL-2, described in a study published in the Journal of Experimental & Clinical Cancer Research. The molecule has two business ends. One is a monovalent antibody fragment that binds the T-cell receptor, the molecular antenna that T cells use to recognize foreign or abnormal cells, at specific residues on its variable beta (Vβ) chain. The other end is interleukin-2, a powerful growth and activation signal for T cells. By physically coupling these two functions, the molecule delivers interleukin-2 selectively to T cells bearing particular TCRβ chains, rather than flooding the entire immune system with the cytokine, a limitation that has historically made IL-2 therapy toxic and poorly targeted.

Because the T-cell receptor’s variable beta chain defines a distinct clonal family of T cells, the drug acts as a selective activator: it stimulates a defined subset of the T-cell repertoire rather than every T cell it encounters. The researchers reasoned that this targeted activation could push exhausted or bystander antitumor T cells back into a functional state, priming them so that a subsequent dose of anti-PD-1 could lock in the revived response. Checkpoint blockade alone often fails precisely because the T cells it is meant to unleash are too depleted to exploit the removal of their molecular brakes.

To test that logic, the team used a panel of syngeneic murine cancer models spanning a spectrum of sensitivity to immune checkpoint inhibition, from relatively responsive tumors to those with pronounced resistance. In the resistant settings, anti-PD-1 alone did what it typically does in patients who do not benefit: it expanded pools of terminally exhausted CD8+ T cells without producing meaningful tumor control. But when the mice received anti-TCRβ-IL-2 first, followed by anti-PD-1, the picture changed dramatically. The combination produced robust anti-tumor efficacy, including complete tumor cures and long-term immune protection against rechallenge in several models that were otherwise refractory to checkpoint therapy.

The mechanistic story emerged from an unusually deep interrogation of the tumor microenvironment. Using flow cytometry, single-cell transcriptomics, and histological analysis of tumor-infiltrating lymphocytes, the investigators found that the sequential regimen increased proliferation and cytotoxic markers, such as granzyme B and interferon-gamma, in both CD8+ and CD4+ T cells within the tumors. At the same time, exhaustion markers on CD8+ T cells declined, and the proportion of immunosuppressive regulatory CD4+ T cells shrank. In other words, the combination did not merely add more T cells to the fight; it shifted the balance of the tumor immune landscape from suppression and dysfunction toward active cytotoxicity.

Perhaps the most striking finding involved the breadth of the immune response. After combination therapy, mice developed multifunctional T-cell responses against tumor-associated antigens and, critically, against neoantigens, the mutant peptides that arise from the cancer’s own genetic alterations. This expansion of antigen-specific reactivity is the immunological hallmark of epitope spreading: as therapy kills tumor cells and releases new antigens, the immune system diversifies its attack beyond the targets it originally recognized. The study observed a marked increase in the number of multifunctional neoantigen-specific T cells in mice receiving the dual activator followed by anti-PD-1, compared with either monotherapy, suggesting that the combination builds a broader and more resilient army against the tumor than checkpoint inhibition can achieve on its own.

The sequencing mattered. Anti-TCRβ-IL-2 followed by anti-PD-1, rather than the reverse order or either agent alone, delivered the strongest effects, consistent with a model in which selective T-cell activation first revives the antitumor fleet and checkpoint blockade then sustains the newly functional cells by removing PD-1-mediated inhibition. Single-cell profiling revealed shifts in the composition and differentiation state of tumor-infiltrating lymphocytes, including evidence of reduced terminal exhaustion and enhanced cytotoxic programming in the CD8+ compartment after the combination.

The clinical implications are immediate. Building on these preclinical results, the researchers announce plans for a clinical trial evaluating the anti-TCRβ-IL-2 agent, known as invikafusp alfa, in combination with anti-PD-1 antibody therapy in patients with immune checkpoint inhibitor-refractory non-small cell lung cancer and castration-resistant metastatic prostate cancer. Both indications represent large patient populations in which resistance to checkpoint blockade is common and better options are urgently needed. If the murine findings translate, the combination could convert a subset of non-responders into durable beneficiaries of immunotherapy.

The work was conducted under a Cooperative Research and Development Agreement between the National Cancer Institute and Marengo Therapeutics, with support from the NCI Intramural Research Program, and was carried out under approved animal care protocols. Several co-authors are employees of Marengo Therapeutics, which is developing the TCRβ-directed platform. The study was published open access, and the authors emphasize that the T-cell activation mechanism it describes, reviving T-cell function and driving epitope spreading, offers a general blueprint for sensitizing refractory tumors to immune checkpoint inhibition rather than a single-drug solution.

For a field grappling with the ceiling of checkpoint immunotherapy, the study reframes the problem: instead of trying to push exhausted T cells harder with blockade alone, it suggests first handing them a targeted activation signal tailored to their receptor, then removing the brakes. In the mouse models reported here, that one-two sequence turned checkpoint failure into long-lasting cures. Whether the same revival can be reproduced in patients with exhausted, treatment-resistant tumors will be the question the planned clinical trials are designed to answer.

Subject of Research: A TCR beta chain-directed selective dual T-cell activator combined with anti-PD-1 to overcome immune checkpoint inhibitor resistance

Article Title: Overcoming immune checkpoint inhibitor-mediated T-cell exhaustion with a TCR β chain-directed selective dual T-cell activator

Article References: Angstadt, S., Horn, L. A., Fousek, K., Rajabian, N., Qin, H., Medina-Enriquez, M. M., Kelly, M. D., Hsiao-Sanchez, N., Meyer, T. J., Moisan, J., Katragadda, M., Bayliffe, A., Su, Z., Schlom, J., & Palena, C. (2026). Overcoming immune checkpoint inhibitor-mediated T-cell exhaustion with a TCR β chain-directed selective dual T-cell activator. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03815-2

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03815-2

Keywords: immune checkpoint inhibitors, T-cell exhaustion, anti-TCRβ-IL-2, PD-1, T-cell receptor, interleukin-2, epitope spreading, neoantigens, tumor microenvironment, invikafusp alfa, immunotherapy resistance, cancer immunotherapy